Trial results
$OBX — amsoki-cel
Obsidian Therapeutics, Inc. (OBX) amsoki-cel: trial results in Immune checkpoint inhibitor-resistant advanced or metastatic melanoma, 2027.
The catalyst
"We remain on track to complete enrollment in the registration-enabling cohort by the end of the first quarter of 2027 and report topline data by year-end 2027."
— Obsidian Therapeutics, 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
OBX-AMSOKICEL-2026- Company
- Obsidian Therapeutics, Inc.
- Kind
- Trial results
- Indication
- Immune checkpoint inhibitor-resistant advanced or metastatic melanoma
- Window
- 2027-01-01 – 2027-12-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.